Literature DB >> 16353594

Comparison of the lipolytic effects of norepinephrine and BRL 37344 in rat brown and white adipocytes.

P M Simard1, C Atgié, P Mauriège, F D'Allaire, L J Bukowiecki.   

Abstract

The lipolytic effects of norepinephrine (a non-selective beta-agonist) and BRL 37344 (a selective beta3-agonist) were compared in isolated rat brown and white adipocytes. Norepinephrine and BRL 37344 maximally stimulated lipolysis in brown and white adipocytes, approximately 10 times above basal values. However, adipocyte sensitivity for BRL 37344 was greater than that for norepinephrine, particularly in brown adipocytes [the EC50 values (nM) for BRL 37344 and norepinephrine were 5 +/- 1 and 103 +/- 31 in brown adipocytes (P < 0.01) versus 56 +/- 9 and 124 +/- 17 in white adipocytes (P < 0.05), respectively]. On the other hand, the lipolytic effects of norepinephrine were totally blocked by 20-40 times superior concentrations of propranolol or bupranolol in brown as well as in white adipocytes. In contrast, the lipolytic effects of BRL 37344 were fully inhibited by concentrations of propranolol or bupranolol that were 200-1000 superior to the beta3 agonist concentration. The results demonstrate that: (1) the beta3-agonist BRL 37344 is as effective as norepinephrine for maximally stimulating lipolysis in rat brown and white adipocytes, (2) both adipocyte types are more sensitive to the lipolytic effects of BRL 37344 than to those of norepinephrine, (3) although bupranolol is a better antagonist than propranolol on BRL 37344-stimulated lipolysis, it cannot be considered as a specific beta3-antagonist, (4) brown adipocytes are 10 times more sensitive than white adipocytes to the lipolytic effects of BRL 37344, suggesting an important role of beta3-receptors in brown adipose tissue.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 16353594     DOI: 10.1002/j.1550-8528.1994.tb00089.x

Source DB:  PubMed          Journal:  Obes Res        ISSN: 1071-7323


  6 in total

1.  Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the beta3-adrenoreceptor.

Authors:  An L Moens; Jordan S Leyton-Mange; Xiaolin Niu; Ronghua Yang; Oscar Cingolani; Elisabeth K Arkenbout; Hunter C Champion; Djahida Bedja; Kathleen L Gabrielson; Juan Chen; Yong Xia; Ashley B Hale; Keith M Channon; Marc K Halushka; Norman Barker; Floris L Wuyts; Pawel M Kaminski; Michael S Wolin; David A Kass; Lili A Barouch
Journal:  J Mol Cell Cardiol       Date:  2009-09-18       Impact factor: 5.000

Review 2.  A pathway and network review on beta-adrenoceptor signaling and beta blockers in cardiac remodeling.

Authors:  Jihong Yang; Yufeng Liu; Xiaohui Fan; Zheng Li; Yiyu Cheng
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

3.  Characterization of beta 1- and beta 3-adrenoceptors in intact brown adipocytes of the rat.

Authors:  F D'Allaire; C Atgié; P Mauriège; P M Simard; L J Bukowiecki
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

Review 4.  Targeting β3-Adrenergic Receptors in the Heart: Selective Agonism and β-Blockade.

Authors:  Alessandro Cannavo; Walter J Koch
Journal:  J Cardiovasc Pharmacol       Date:  2017-02       Impact factor: 3.105

Review 5.  Spotlight on ROS and β3-Adrenoreceptors Fighting in Cancer Cells.

Authors:  Maura Calvani; Angela Subbiani; Marina Vignoli; Claudio Favre
Journal:  Oxid Med Cell Longev       Date:  2019-12-14       Impact factor: 6.543

6.  β3-Adrenoreceptor stimulation protects against myocardial infarction injury via eNOS and nNOS activation.

Authors:  Xiaolin Niu; Lianyou Zhao; Xue Li; Yusheng Xue; Bin Wang; Zongqiang Lv; Jianghong Chen; Dongdong Sun; Qiangsun Zheng
Journal:  PLoS One       Date:  2014-06-09       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.